April 20, 2022
1 min watch
Save
VIDEO: Nyxol trial shows positive results for mydriasis reversal
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
NEW YORK – A phase 3 FDA registration trial for Ocuphire Pharma’s Nyxol yielded positive topline results for the reversal of mydriasis, according to a company executive.
Bindu Manne, who heads up market development and commercialization for Ocuphire, said the preservative-free eye drop formulation of phentolamine mesylate is also being studied for presbyopia and night vision disturbances.
Published by:
Sources/Disclosures
Collapse
Disclosures:
Manne reports being employed by Ocuphire Pharma.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.